Literature DB >> 12173717

Beta-blockers: new standard therapy for heart failure.

Allison M Pritchett1, Margaret M Redfield.   

Abstract

Despite recent advances in the diagnosis and treatment of cardiovascular disease, the prevalence of heart failure, a highly morbid and lethal condition, is increasing. Because of recent advances in basic and clinical research, beta-blockade is now established as a highly effective therapy that reduces morbidity and mortality dramatically in patients with heart failure associated with reduced systolic function. The new guidelines from the American College of Cardiology-American Heart Association recommend use of beta-blockers in all patients with symptomatic left ventricular systolic dysfunction. Now clinicians need to incorporate use of beta-blockers into their standard approach to the treatment of heart failure. We briefly summarize the basic and clinical evidence establishing the benefit of beta-blockers for heart failure and provide practical information to assist clinicians in deciding when and how to use beta-blockers in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173717     DOI: 10.4065/77.8.839

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

Review 1.  Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.

Authors:  Kristin E Ellison; Gaurang Gandhi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A myth of ophthalmic beta-blockers therapy.

Authors:  Weekitt Kittisupamongkol
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-20       Impact factor: 3.117

3.  Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.

Authors:  Tomoaki Nakata; Takeru Wakabayashi; Michifumi Kyuma; Toru Takahashi; Kazufumi Tsuchihashi; Kazuaki Shimamoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-25       Impact factor: 9.236

4.  Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists.

Authors:  Peter L Freddolino; M Yashar S Kalani; Nagarajan Vaidehi; Wely B Floriano; Spencer E Hall; Rene J Trabanino; Victor Wai Tak Kam; William A Goddard
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.